Luye Pharma GroupFRA:LUP +3.03%47 Net Margin % is 9.78% as of Dec. 2025, which is 15% below its 10-year median of 11.44. GuruFocus rates FRA:LUP with a GF Score™ of 47/100 and a GF Value™ of €0.32 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 955 Drug Manufacturers companies, Luye Pharma Group ranks better than 63.25% on this metric.
The historical rank and industry rank for Luye Pharma Group's Net Margin % or its related term are showing as below:
FRA:LUP'
s Net Margin % Range Over the Past 10 Years
Min: -2.58 Med: 11.44 Max: 30.56
Current: 9.81
FRA:LUP's Net Margin % is ranked better than 63.25% of 955
companies
in the Drug Manufacturers industry
Industry Median: 5.69
vs FRA:LUP: 9.81
Luye Pharma Group (FRA:LUP) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Luye Pharma Group Net Margin % Related Terms
Luye Pharma Group Net Margin % Historical Data
* Premium members only.
The historical data trend for Luye Pharma Group's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Luye Pharma Group's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Luye Pharma Group Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Luye Pharma Group's Net Margin % distribution charts can be found below:
* The bar in red indicates where Luye Pharma Group's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Luye Pharma Group (FRA:LUP) has a Net Margin % of 9.78% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Luye Pharma Group and its competitors. This is 15% below median its historical median of 11.44. According to the industry distribution chart, Luye Pharma Group ranks #351 out of 955 companies in the Drug Manufacturers industry, placing it in the top 36.8%.
Is Luye Pharma Group's Net Margin % too high?
Luye Pharma Group's current Net Margin % of 9.78% is 15% below median its 10-year median of 11.44. The Drug Manufacturers industry median Net Margin % is 5.69. Luye Pharma Group's value of 9.78% is 71.9% above this industry median. Based on the distribution chart, Luye Pharma Group ranks #351 out of 955 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Luye Pharma Group has a GF Score™ of 47/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Luye Pharma Group's Net Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Luye Pharma Group ranks #351 out of 955 companies for Net Margin %. This puts Luye Pharma Group in the upper half of its industry. The industry median Net Margin % is 5.69. Luye Pharma Group's value of 9.78% is 71.9% above this benchmark. While the company's 10-year median is 11.44 vs. the industry median of 5.69, Luye Pharma Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.69, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Luye Pharma Group's current Net Margin % of 9.78% is 71.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Luye Pharma Group and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Luye Pharma Group's current Net Margin % is 9.78%, which is 15% below median its own 10-year median of 11.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Luye Pharma Group stock overvalued right now?
Based on GuruFocus' analysis, Luye Pharma Group (FRA:LUP) is currently considered Possible Value Trap. The stock's GF Value™ is €0.32, compared to a current price of €0.20 — trading 36.3% below its estimated fair value. The current Net Margin % is 9.78%, which is 15% below median its 10-year median of 11.44 and 71.9% above the Drug Manufacturers industry median of 5.69. Luye Pharma Group's overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Luye Pharma Group (FRA:LUP), the current Net Margin % is 9.78% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Luye Pharma Group (FRA:LUP) Overvalued in 2026?
Based on GuruFocus' analysis, Luye Pharma Group stock appears to be undervalued.
The current stock price of €0.20 is trading 36.3% below its estimated GF Value™ of €0.32.
GuruFocus considers Luye Pharma Group to be Possible Value Trap.
Key valuation signals for FRA:LUP:
Net Margin %: 9.78% (15% below median its 10-year median of 11.44)
GF Value™: €0.32 vs. price of €0.20 (36.3% below fair value)
Industry Position: 71.9% above the Drug Manufacturers median (#351 of 955)
No single metric tells the full story. See the FRA:LUP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Luye Pharma Group Ltd is a China-based drug manufacturer that focuses on development, production, marketing and sale of pharmaceutical products. The company develops drugs related to diagnosing and treating cancer, the cardiovascular system, the alimentary tract, and the central nervous system. The company develops drugs for world-wide use in Asia, Europe, and the United States. The Group organizes its business segments by type of products. Oncology drugs, which derives maximum revenue; Cardiovascular system drugs; Alimentary tract and metabolism drugs; Central nervous system drugs; and others. Geographically, the group derives maximum revenue from Chinese Mainland, while it also has its presence in Asia (other than the Chinese mainland), European Union, and Other countries.
47GF Score
Get the complete analysis for FRA:LUP
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:LUP has been successfully added to your 
